Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
Add more filters










Database
Language
Publication year range
1.
Bioanalysis ; 4(15): 1883-94, 2012 Aug.
Article in English | MEDLINE | ID: mdl-22943619

ABSTRACT

Biomarkers have become increasingly important in drug development and many bioanalysts are getting involved. Consequently, different views on how to approach the bioanalysis of biomarkers have been published or are being developed. The European Bioanalysis Forum has intensively discussed this topic since 2010 and is ready with their recommendation on method establishment and bioanalysis of biomarkers. Acknowledging that the challenges step outside the bioanalytical laboratory is a cornerstone of our recommendation. The importance of integrating all scientific aspects, from purely analytical aspects, all the way to understanding the biology and effects of the biomarker, prior to embarking on method establishment or sample analysis, cannot be underestimated. Close and iterative interactions with the teams requesting the data is imperative to develop a bioanalytical strategy that combines science, analytical performance and regulations. The European Bioanalysis Forum developed a straightforward decision tree to help the scientific community in developing a bioanalytical strategy for any biomarker in drug development.


Subject(s)
Biomarkers, Pharmacological/analysis , Drug Discovery/standards , Animals , Biomarkers, Pharmacological/metabolism , Europe , Evaluation Studies as Topic , Government Regulation , Humans , Reproducibility of Results , Sensitivity and Specificity
2.
Bioanalysis ; 4(6): 633-42, 2012 Mar.
Article in English | MEDLINE | ID: mdl-22452252

ABSTRACT

The 4th Open Symposium of the European Bioanalytical Forum entitled 'Less is More' was held on 16-18 November 2011 at the Hesperia Tower Hotel, Barcelona, Spain. More than 50 interesting presentations were delivered covering areas with interest for the small- and large-molecule community - biomarker validation; regulations, including an update on new and emerging guidelines and on Global harmonization; technology updates; incurred sample stability; microdosing; dried blood spots and microsampling; challenges of 'free' and 'total' macromolecule quantification; stability issues in ligand binding assays or anomalous results. In excess of 450 delegates from more than 170 institutes and companies (industry, regulators and academia) from all global regions participated in the open and stimulating discussions. This manuscript provides an overview of the highlights discussed at the meeting.


Subject(s)
Biomarkers/analysis , Chromatography, Liquid , Dried Blood Spot Testing , Guidelines as Topic , Mass Spectrometry , Pharmacokinetics
3.
Bioanalysis ; 3(8): 833-8, 2011 Apr.
Article in English | MEDLINE | ID: mdl-21510756

ABSTRACT

The European Bioanalysis Forum is a bioanalytical nonprofit organization comprised of European pharmaceutical companies (27 members to date) and currently expanding to include CROs as well. The European Bioanalysis Forum provides a broad European bioanalytical network for the discussion of scientific, technological and regulatory topics of bioanalytical interest. The 3rd Annual Open Symposium was again much anticipated after the two previous successful meetings. The symposium included sessions on thinking outside the 'commodity' box, bioanalytical challenges with blood, global harmonization, assay platforms, dried blood spots, immunogenicity, matrix effects, anomalous results, biomarkers and two plenary technology sessions hosted by the Platinum sponsors. Experts and key opinion leaders were invited as guest speakers. A total of 424 delegates registered from 113 companies representing a large percentage of the European bioanalytical community. In addition to 48 oral presentations, 88 posters were presented and there was a vendor exposition of 40 companies.


Subject(s)
Clinical Chemistry Tests/methods , Drug Industry , Biological Assay , Biomarkers/analysis , Clinical Chemistry Tests/standards , Clinical Chemistry Tests/trends , Europe , Organizations, Nonprofit , Pharmaceutical Preparations/analysis
4.
Am J Pathol ; 166(2): 433-42, 2005 Feb.
Article in English | MEDLINE | ID: mdl-15681827

ABSTRACT

Dipeptidyl peptidase IV (DPPIV, CD26), a protease-cleaving N-terminal X-Pro dipeptide from selected proteins including some chemokines, is expressed both as a soluble form in plasma and on the cell surface of various immune and nonimmune cell types. To gain insights into the pathophysiological role of CD26 in arthritis, we explored DPPIV/CD26 expression during murine antigen-induced arthritis (AIA), an experimental model of arthritis. AIA induction led to reduced plasma DPPIV activity. In CD26-deficient mice, the severity of AIA was increased as assessed by enhanced technetium uptake and by increased histological parameters of inflammation (synovial thickness and exudate). We demonstrated that CD26 controls the in vivo half-life of the intact active form of the proinflammatory chemokine stromal cell-derived factor-1 (SDF-1). CD26-deficient mice exhibited increased levels of circulating active SDF-1, associated with increased numbers of SDF-1 receptor (CXCR4)-positive cells infiltrating arthritic joints. In a clinical study, plasma levels of DPPIV/CD26 from rheumatoid arthritis patients were significantly decreased when compared to those from osteoarthritis patients and inversely correlate with C-reactive protein levels. In conclusion, decreased circulating CD26 levels in arthritis may influence CD26-mediated regulation of the chemotactic SDF-1/CXCR4 axis.


Subject(s)
Arthritis, Experimental/blood , Arthritis/blood , Dipeptidyl Peptidase 4/blood , Dipeptidyl Peptidase 4/physiology , Aged , Animals , Cell Proliferation , Chemokine CXCL12 , Chemokines, CXC/metabolism , Chemotaxis , Enzyme-Linked Immunosorbent Assay , Female , Humans , Immunohistochemistry , Inflammation , Interferon-gamma/metabolism , Lymph Nodes/pathology , Male , Mass Spectrometry , Mice , Mice, Inbred C57BL , Mice, Knockout , Middle Aged , Osteoarthritis/metabolism , Peptides/chemistry , Receptors, CXCR4/metabolism , Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization , T-Lymphocytes/metabolism , Time Factors
5.
Exp Appl Acarol ; 32(3): 151-70, 2004.
Article in English | MEDLINE | ID: mdl-15139081

ABSTRACT

Laboratory experiments with Lepidoglyphus destructor on a diet of mainly whole wheat were conducted to study the mite's development and production of a specific allergen, Lep d 2, at four different temperatures (5, 10, 15 and 20 degrees C) and three levels of relative humidity (ca. 70-88%). Statistical models were used to analyse the role played by temperature, relative humidity and time in explaining the observed number of L. destructor and the amount of allergen produced. Moreover, the life stage distributions of the mites were determined and related to the population growth. Based on a statistical model the intrinsic rate of natural increase, rm, was computed for a range of different temperatures and relative humidities. High relative humidity in combination with temperatures at about 25 degrees C will lead to the highest rm (ca. 0.15 day-1). The highest concentration of Lep d 2 was 3 micrograms g-1 grain, found at 20 degrees C and high relative humidity at a mite density of 254 mites g-1 grain. The concentration of allergens in the grain was best explained by a model that incorporated both the current and the cumulative numbers of mites.


Subject(s)
Acaridae/growth & development , Allergens/immunology , Insect Proteins/immunology , Proteins/immunology , Acaridae/immunology , Allergens/biosynthesis , Animals , Edible Grain/parasitology , Enzyme-Linked Immunosorbent Assay , Female , Humidity , Insect Proteins/biosynthesis , Male , Models, Immunological , Protein Biosynthesis , Temperature
SELECTION OF CITATIONS
SEARCH DETAIL
...